[go: up one dir, main page]

EP1989210A2 - Antagonistes du recepteur a2a de l'adenosine - Google Patents

Antagonistes du recepteur a2a de l'adenosine

Info

Publication number
EP1989210A2
EP1989210A2 EP07757782A EP07757782A EP1989210A2 EP 1989210 A2 EP1989210 A2 EP 1989210A2 EP 07757782 A EP07757782 A EP 07757782A EP 07757782 A EP07757782 A EP 07757782A EP 1989210 A2 EP1989210 A2 EP 1989210A2
Authority
EP
European Patent Office
Prior art keywords
dihydrothiopheno
methyl
dione
ethyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07757782A
Other languages
German (de)
English (en)
Inventor
Elfatih Elzein
Rao Kalla
Jeff Zablocki
Xiaofen Li
Thao Perry
Tetsuya Kobayashi
Eric Parkhill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of EP1989210A2 publication Critical patent/EP1989210A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to novel compounds that are A 2A adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as obesity, CNS disorders, including the "movement disorders” (Parkinson's disease, Huntington's Chorea, and catelepsy), cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids), and to their use in enhancing immune response.
  • the invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
  • adenosine receptors which are subdivided into four general subtypes; Aj, A 2A , A 2B , and A 3 , all of which modulate important physiological processes ((G. L. Stiles, K. A. Jacobson, and M. F. Jarvis, Wiley-Liss: New York, (1997); pp 29-37; V. Ralevic; G. Burnstock, G. Pharmacol. Rev. (1998) Vol.50, 413-492).
  • stimulation of the Ai adenosine receptors shortens the duration and decreases the amplitude of the action potential of AV nodal cells, and hence prolongs the refractory period of the AV nodal cell.
  • stimulation of Ai receptors provides a method of treating supraventricular tachycardias, including termination of nodal re-entrant tachycardias, and control of ventricular rate during atrial fibrillation and flutter.
  • Stimulation of cell surface A 2A receptors produces dilation of the coronary resistance vessels, which phenomenon is useful for pharmacological stress imaging.
  • a 2B receptors have been implicated in mast cell activation, asthma, vasodilation, regulation of cell growth, intestinal function, and modulation of neurosecretion (See Adenosine A 2B Receptors as Therapeutic Targets, Drug Dev Res 45:198; Feoktistov et al., Trends Pharmacol Sci 19:148-153).
  • a 3 adenosine receptors modulate cell proliferation processes.
  • compounds that are A 3 receptor agonists have utility in the therapeutic and/or prophylactic treatment of cancer, cardiac disease, infertility, kidney disease, and CNS disorders.
  • Adenosine is an important endogenous purine neuromodulator in the central nervous system. Recently, A 2A receptors have been demonstrated to be abundant in the basal ganglia, a region of the brain that is known to be important in motor function.
  • haloperidol or MPTP N-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine
  • haloperidol or MPTP N-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine
  • MPTP N-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine
  • a 2A receptor antagonist see, for example, "Piperazine Derivatives of [1,2,4] Triazolo[l,5- a][l,3,5]triazine as Potent and Selective Adenosine A 2A Receptor Antagonists", by Chi B. Vu et al., Journal of Medicinal Chemistry, 2004).
  • a 2A receptor antagonists also possess neuroprotective properties.
  • a 2A antagonists have been shown to block kainate-induced excitotoxicity in the hippocampus, to reduce ischemia-evoked glutamate and aspartate release from the cortex, and to reduce the extent of the ischemia-induced injury in rats and gerbils. Further evidence for A 2A receptor mediated neuroprotection arises from studies demonstrating that both cerebral infarct size and neurological deficits following transient ischemia are attenuated in A 2A receptor knockout mice.
  • Stimulation of A 2A adenosine receptors produces dilation of the coronary resistance vessels. Although this phenomenon is useful for pharmacological stress imaging, it is not favorable for patients who have elevated endogenous adenosine, because excessive vasodilation potentially leads to coronary steal.
  • the phenomenon of coronary steal can cause tissue damage, because ischemia may be produced in the vascular beds fed by the artery that has lowered blood flow due to the more favorable vasodilation of healthy adjoining arteries. Accordingly, an A 2A antagonist will prevent the phenomenon of coronary steal.
  • adenosine signaling is implicated in drug addiction. All major drugs of abuse (opiates, cocaine, ethanol, and the like) either directly or indirectly modulate dopamine signaling in neurons, in particular those found in the nucleus accumbens, which contains high levels OfA 2A adenosine receptors. Dependence on addictive substances has been shown to be augmented by the adenosine signaling pathway, and it has been shown that administration of an A 2A adenosine receptor antagonist reduces the craving for addictive substances (see.
  • adenosine receptors in particular the A 2A adenosine receptor, play a role in down regulation of inflammation in vivo (see U.S. Patent Application Publication No. 2005/0220799) by acting as a termination mechanism that limits the immune response, and consequently protect normal tissues from excess immune damage during pathogenesis of various diseases. Accordingly, inhibition of signaling through the A 2A adenosine receptor intensifies and prolongs the immune response in a mammal, and thus, for example, increases the efficacy of a vaccine when an A 2 A adenosine antagonist is co-administered with a vaccine.
  • the compounds are potent A 2A antagonists, useful in the treatment of various disease states related to modulation of the A 2A receptor, in particular cardiovascular diseases such as tissue damage caused by ischemia, CNS-related diseases such as Parkinson's Disease, the treatment of drug addiction, and improved immunization.
  • cardiovascular diseases such as tissue damage caused by ischemia
  • CNS-related diseases such as Parkinson's Disease
  • the compounds would be selective for the A 2A receptor, thus avoiding side effects caused by interaction with other adenosine receptors.
  • the invention relates to compounds of Formula I: wherein a.
  • R 1 is hydrogen, optionally substituted Ci -4 alkyl, optionally substituted C 2-4 alkenyl, or optionally substituted C 2-4 alkynyl;
  • R 2 is hydrogen, optionally substituted Cj -4 alkyl, or a 5 or 6 membered optionally substituted monocyclic heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, sulfur and nitrogen; c.
  • R 3 is hydrogen, -C(O)NR 5 R 6 , in which R 5 and R 6 are independently selected from hydrogen, optionally substituted lower alkyl, or R 3 is an optionally substituted 5 or 6 membered monocyclic heterocycle or heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, sulfur and nitrogen; or d.
  • R 2 and R 3 taken together are an optionally substituted alkylene group which combine to form a 5 or 6 membered optionally substituted cyclic alkenyl ring, or a 5 or 6 membered heterocyclic ring in which the heteroatoms are oxygen or nitrogen; and e.
  • R 4 is hydrogen or optionally substituted Ci -4 alkyl, f. or a pharmaceutically acceptable salt, ester, prodrug, hydrate, or polymorph thereof.
  • compositions comprising a therapeutically effective amount of an A 2A receptor antagonist of Formula I, and at least one pharmaceutically acceptable carrier.
  • the formulation is preferably for oral administration.
  • a third embodiment of the invention methods of using the compounds of Formula I in the treatment of a disease or condition in a mammal that can be treated with an A 2A receptor antagonist are provided.
  • the method comprises administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I.
  • diseases include, but are not limited to, obesity, Parkinson's disease, Huntington's Chorea, and catelepsy, and cerebral ischemia, excitotoxicity, and cognitive and physiological disorders, including the treatment of drug addiction.
  • the compounds of Formula I are also useful for the inhibition of coronary vasodilation, which treatment prevents coronary steal.
  • the invention relates to compounds of Formula II:
  • R 1 is hydrogen, optionally substituted Ci -4 alkyl, optionally substituted C 2 - 4 alkenyl, or optionally substituted C 2 - 4 alkynyl;
  • R 2 is hydrogen, optionally substituted Ci -4 alkyl, or a 5 or 6 membered optionally substituted monocyclic heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, sulfur and nitrogen;
  • R 3 is -COOR 7 , -C(O)R 8 , or optionally substituted lower alkyl, in which R 7 is hydrogen or optionally substituted lower alkyl, and R 8 is hydrogen or optionally substituted lower alkyl;
  • R 4 is hydrogen or optionally substituted C 1 - 4 alkyl.
  • the preferred compounds for use in the invention include, but are not limited to:
  • alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-decyl, tetradecyl, and the like.
  • substituted alkyl refers to:
  • alkyl group as defined above, having 1, 2, 3, 4 or 5 substituents, preferably 1 to 3 substituents, selected from the group consisting of alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, -SO 2 -alkyl, SO
  • substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyl, aryl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2; or 2) an alkyl group as defined above that is interrupted by 1-10 atoms independently chosen from oxygen, sulfur and NR 3 -, where R a is chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl.
  • substituents may be optionally further substituted by alkyl, aryl, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, or -S(O) n R, in which R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2; or
  • lower alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having 1, 2, 3, 4, 5, or 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t- butyl, n-hexyl, and the like.
  • substituted lower alkyl refers to lower alkyl as defined above having 1 to 5 substituents, preferably 1 , 2, or 3 substituents, as defined for substituted alkyl, or a lower alkyl group as defined above that is interrupted by 1, 2, 3, 4, or 5 atoms as defined for substituted alkyl, or a lower alkyl group as defined above that has both 1 , 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1, 2, 3, 4, or 5 atoms as defined above.
  • alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms, preferably 1-10 carbon atoms, more preferably 1, 2, 3, 4, 5 or 6 carbon atoms.
  • This term is exemplified by groups such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), the propylene isomers (e.g., -CH 2 CH 2 CH 2 - and-CH(CH 3 )CH r ) and the like.
  • lower alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1, 2, 3, 4, 5, or 6 carbon atoms.
  • lower alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, preferably having from 1, 2, 3, 4, 5, or 6 carbon atoms.
  • substituted alkylene refers to:
  • an alkylene group as defined above having 1, 2, 3, 4, or 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, arainosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, -SO 2 -alkyl, SO 2 -ary
  • substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2; or
  • an alkylene group as defined above that is interrupted by 1 -20 atoms independently chosen from oxygen, sulfur and NR 3 -, where R a is chosen from hydrogen, optionally substituted alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycyl, or groups selected from carbonyl, carboxyester, carboxyamide and sulfonyl; or
  • alkylene group as defined above that has both 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1-20 atoms as defined above.
  • substituted alkylenes are chloromethylene (-CH(Cl)-), aminoethylene (-CH(NH 2 )CH 2 -), methylaminoethylene (-CH(NHMe)CH 2 -), 2- carboxypropylene isomers(-CH 2 CH(CO 2 H)CH 2 -), ethoxyethyl (-CH 2 CH 2 O- CH 2 CH 2 -), ethylmethylammoethyl (-CH 2 CH 2 N(CH 3 )CH 2 CH 2 -), 1 -ethoxy-2-(2- ethoxy-ethoxy)ethane (-CH 2 CH 2 O-CH 2 CH 2 -OCH 2 CH 2 -OCH 2 CH 2 -), and the like.
  • aralkyl refers to an aryl group covalently linked to an alkylene group, where aryl and alkylene are defined herein.
  • Optionally substituted aralkyl refers to an optionally substituted aryl group covalently linked to an optionally substituted alkylene group.
  • Such aralkyl groups are exemplified by benzyl, phenylethyl, 3-(4-methoxyphenyl)propyl, and the like.
  • alkoxy refers to the group R-O-, where R is optionally substituted alkyl or optionally substituted cycloalkyl, or R is a group -Y-Z, in which Y is optionally substituted alkylene and Z is optionally substituted alkenyl, optionally substituted alkynyl; or optionally substituted cycloalkenyl, where alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl are as defined herein.
  • Preferred alkoxy groups are optionally substituted alkyl-O- and include, by way of example, methoxy, ethoxy, n- propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1 ,2- dimethylbutoxy, trifluoromethoxy, and the like.
  • alkylthio refers to the group R-S-, where R is as defined for alkoxy.
  • alkenyl refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 20 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having 1-6, preferably 1, double bond (vinyl).
  • lower alkenyl refers to alkenyl as defined above having from 2 to 6 carbon atoms.
  • substituted alkenyl refers to an alkenyl group as defined above having 1, 2, 3, 4 or 5 substituents, and preferably 1, 2, or 3 substituents, selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -
  • substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • alkynyl refers to a monoradical of an unsaturated hydrocarbon, preferably having from 2 to 20 carbon atoms, more preferably 2 to 10 carbon atoms and even more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-6 sites of acetylene (triple bond) unsaturation.
  • Preferred alkynyl groups include ethynyl, (-C ⁇ CH), propargyl (or prop-l-yn-3-yl, -CH 2 C ⁇ CH), and the like. In the event that alkynyl is attached to nitrogen, the triple bond cannot be alpha to the nitrogen.
  • substituted alkynyl refers to an alkynyl group as defined above having 1, 2, 3, 4 or 5 substituents, and preferably 1, 2, or 3 substituents, selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl,
  • substituents may optionally be further substituted by 1 , 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • aminocarbonyl refers to the group -C(O)NRR where each R is independently hydrogen, alkyl, aryl, heteroaryl, heterocyclyl or where both R groups are joined to form a heterocyclic group (e.g., morpholino). Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • acylamino refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, aryl, heteroaryl, or heterocyclyl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • acyloxy refers to the groups -O(O)C-alkyl, -O(O)C-cycloalkyl, - O(O)C-aryl, -O(O)C-heteroaryl, and -O(O)C-heterocyclyl. Unless otherwise constrained by the definition, all substituents may be optionally further substituted by alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, or -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • aryl refers to an aromatic carbocyclic group of 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple rings (e.g., biphenyl), or multiple condensed (fused) rings (e.g., naphthyl or anthryl).
  • Preferred aryls include phenyl, naphthyl and the like.
  • arylene refers to a diradical of an aryl group as defined above. This term is exemplified by groups such as 1 ,4-phenylene, 1,3-phenylene, 1 ,2-phenylene, l,4'-biphenylene, and the like.
  • aryl or arylene groups can optionally be substituted with from 1 to 5 substituents, preferably 1 to 3 substituents, selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and - S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • aryloxy refers to the group aryl-O- wherein the aryl group is as defined above, and includes optionally substituted aryl groups as also defined above.
  • arylthio refers to the group R-S-, where R is as defined for aryl.
  • amino refers to the group -NH 2 .
  • substituted amino refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, carboxyalkyl (for example, benzyloxycarbonyl), aryl, heteroaryl and heterocyclyl provided that both R groups are not hydrogen, or a group -Y-Z, in which Y is optionally substituted alkylene and Z is alkenyl, cycloalkenyl, or alkynyl, Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and - S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • Carboxyalkyl refers to the groups -C(O)O-alkyl or -C(O)O- cycloalkyl, where alkyl and cycloalkyl, are as defined herein, and may be optionally further substituted by alkyl, alkenyl, alkynyl, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, or -S(O) n R, in which R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • cycloalkyl refers to carbocyclic groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, bicyclo[2.2.1]heptane, l,3,3-trimethylbicyclo[2.2.1]hept-2-yl, (2,3,3- trimethylbicyclo[2.2.1]hept-2-yl), or carbocyclic groups to which is fused an aryl group, for example indane, and the like.
  • substituted cycloalkyl refers to cycloalkyl groups having 1, 2, 3, 4 or 5 substituents, and preferably 1 , 2, or 3 substituents, selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO- alkyl,
  • substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and - S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • halogen refers to fluoro, bromo, chloro, and iodo.
  • acyl denotes a group -C(O)R, in which R is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • heteroaryl refers to a radical derived from an aromatic cyclic group (i.e., fully unsaturated) having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 carbon atoms and 1, 2, 3 or 4 heteroatoms selected from oxygen, nitrogen and sulfur within at least one ring.
  • Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl, benzothiazolyl, or benzothienyl).
  • heteroaryls include, but are not limited to, [l,2,4]oxadiazole, [l ,3,4]oxadiazole, [l,2,4]thiadiazole, [l,3,4]thiadiazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, and the like as well as N-
  • heteroaryl or heteroarylene groups can be optionally substituted with 1 to 5 substituents, preferably 1 to 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and -S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • heteroarylkyl refers to a heteroaryl group covalently linked to an alkylene group, where heteroaryl and alkylene are defined herein.
  • Optionally substituted heteroaralkyl refers to an optionally substituted heteroaryl group covalently linked to an optionally substituted alkylene group.
  • Such heteroaralkyl groups are exemplified by 3-pyridylmethyl, quinolin-8-ylethyl, 4-methoxythiazol-2-ylpropyl, and the like.
  • heteroaryloxy refers to the group heteroaryl-O-.
  • heterocyclyl refers to a monoradical saturated or partially unsaturated group having a single ring or multiple condensed rings, having from 1 to 40 carbon atoms and from 1 to 10 hetero atoms, preferably 1 , 2, 3 or 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring.
  • Heterocyclic groups can have a single ring or multiple condensed rings, and include tetrahydrofuranyl, morpholino, piperidinyl, piperazino, dihydropyridino, and the like.
  • heterocyclic groups can be optionally substituted with 1, 2, 3, 4 or 5, and preferably 1, 2 or 3 substituents, selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO- alkyl, -SO-
  • substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, carboxyalkyl, cycloalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF 3 , amino, substituted amino, cyano, and - S(O) n R, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
  • thiol refers to the group -SH.
  • substituted alkylthio refers to the group -S-substituted alkyl.
  • heteroarylthiol refers to the group -S-heteroaryl wherein the heteroaryl group is as defined above including optionally substituted heteroaryl groups as also defined above.
  • sulfoxide refers to a group -S(O)R, in which R is alkyl, aryl, or heteroaryl.
  • substituted sulfoxide refers to a group -S(O)R, in which R is substituted alkyl, substituted aryl, or substituted heteroaryl, as defined herein.
  • sulfone refers to a group -S(O) 2 R, in which R is alkyl, aryl, or heteroaryl.
  • substituted sulfone refers to a group -S(O) 2 R, in which R is substituted alkyl, substituted aryl, or substituted heteroaryl, as defined herein.
  • keto refers to a group -C(O)-.
  • thiocarbonyl refers to a group -C(S)-.
  • carboxy refers to a group -C(O)-OH.
  • compound of Formula I and Formula II is intended to encompass the compounds of the invention as disclosed, and the pharmaceutically acceptable salts, pharmaceutically acceptable esters, prodrugs, hydrates and polymorphs of such compounds. Additionally, the compounds of the invention may possess one or more asymmetric centers, and can be produced as a racemic mixture or as individual enantiomers or diastereoisomers. The number of stereoisomers present in any given compound of Formula I depends upon the number of asymmetric centers present (there are 2" stereoisomers possible where n is the number of asymmetric centers).
  • the individual stereoisomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolution of the compound of Formula I by conventional means.
  • the individual stereoisomers (including individual enantiomers and diastereoisomers) as well as racemic and non- racemic mixtures of stereoisomers are encompassed within the scope of the present invention, all of which are intended to be depicted by the structures of this specification unless otherwise specifically indicated.
  • Stepoisomers are isomers that differ only in the way the atoms are arranged in space.
  • Enantiomers are a pair of stereoisomers that are non-superimposable mirror images of each other.
  • a 1 :1 mixture of a pair of enantiomers is a “racemic” mixture.
  • the term “( ⁇ )” is used to designate a racemic mixture where appropriate.
  • Diastereoisomers are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system.
  • the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown are designated (+) or (-) depending on the direction (dextro- or laevorotary) which they rotate the plane of polarized light at the wavelength of the sodium D line.
  • Topical administration shall be defined as the delivery of the therapeutic agent to the surface of the wound and adjacent epithelium.
  • Parental administration is the systemic delivery of the therapeutic agent via injection to the patient.
  • therapeutically effective amount refers to that amount of a compound of Formula I that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment.
  • the therapeutically effective amount will vary depending upon the specific activity of the therapeutic agent being used, and the age, physical condition, existence of other disease states, and nutritional status of the patient. Additionally, other medication the patient may be receiving will effect the determination of the therapeutically effective amount of the therapeutic agent to administer.
  • treatment means any treatment of a disease in a mammal, including:
  • the compounds of this invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • pharmaceutically acceptable salt refers to salts that retain the biological effectiveness and properties of the compounds of Formula I, and which are not biologically or otherwise undesirable.
  • Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkeny
  • Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenedi amine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • opioid as used herein includes morphine, codeine, heroin, oxycodone (OxyContin), propoxyphene (Darvon), hydrocodone (Vicodin), and hydromorphone (Dilaudid), as well as meperidine (Demerol)
  • solvent inert organic solvent
  • inert solvent mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like].
  • THF tetrahydrofuran
  • DMF dimethylformamide
  • chloroform chloroform
  • methylene chloride or dichloromethane
  • the compound of formula (1) is commercially available. Initially, a carboxylic acid of formula R 1 CO 2 H is reacted with diphenylphosphoryl azide and a base, and the resulting mixture reacted with a compound of formula (1) to provide a compound of formula (2).
  • the carboxylic acid is dissolved in an inert solvent, for example benzene or toluene, and diphenylphosphoryl azide and a tertiary organic base added, for example triethylamine, and the mixture stirred at reflux for about 1 hour.
  • the compound of formula (1) is then added and the mixture reflux ed for about 10-24 hours.
  • the product of formula (2) is isolated by conventional means, for example by partitioning between ethyl acetate and water and purifying the product, for example by chromatography or recrystallization.
  • reaction of (1) with a carboxylic acid of formula R 1 CO 2 H in the presence of diphenylphosphoryl azide and a base is in effect reaction of (1) with an isocyanate of the formula R 1 NCO.
  • isocyanates are commercially available, or may be prepared by means well known in the art, and can be used directly in the above reaction in place of a mixture OfR 1 CO 2 H, diphenylphosphoryl azide and a base.
  • Step 2 Preparation of a Compound of Formula I in which R » 3 i •s Hydrogen
  • the compound of formula (2) is cyclized to a compound of Formula I by reaction with an alkoxide in a protic solvent, for example sodium ethoxide in ethanol.
  • a protic solvent for example sodium ethoxide in ethanol.
  • the reaction is conducted at about room temperature for about 1-8 hours.
  • the product of Formula I in which R 3 is hydrogen is isolated and purified by conventional means.
  • the compound of formula (3) is reacted with a compound of the formula R 3 B(OH) 2 , which is commercially available or prepared by means well known in the art, in the presence of a catalytic amount of tetrakis(triphenylphosphine)palladium.
  • the compound of formula (3) is dissolved in an inert solvent, for example dimethoxyethane, and the compound of formula R 3 B(OH) 2 added, followed by the palladium catalyst and aqueous sodium carbonate solution.
  • the reaction is conducted at a temperature of about reflux, for about 8-24 hours.
  • the product of Formula I is isolated and purified by conventional means, for example by partitioning between ethyl acetate and water. Removal of the solvent provides a crude compound of Formula I, which may be further purified by crystallization from an inert solvent, for example ethyl acetate.
  • the compound of formula (4) is commercially available. Initially, a carboxylic acid of formula R 1 CO 2 H is reacted with diphenylphosphoryl azide and a base, for example triethylamine, in an inert solvent, for example toluene at reflux for about 1.5 hours. The mixture is then cooled to below 4O 0 C, the compound of formula (4) added, and the mixture refluxed for about 24 hours. When the reaction is substantially complete, the product of formula (5) is isolated by conventional means, for example by partitioning between ethyl acetate and water and purifying the product, for example by chromatography.
  • a base for example triethylamine
  • the compound of formula (5) is cyclized to a compound of formula (6) by reaction with an alkoxide in a protic solvent, for example sodium ethoxide in ethanol.
  • a protic solvent for example ethanol
  • an alkoxide for example sodium ethoxide
  • the mixture is maintained at room temperature for about 4-24 hours, for example overnight.
  • the product of formula (6) is isolated and purified by conventional means, for example by acidifying the mixture and removing the solvent under reduced pressure.
  • the compound of formula (6) is then hydrolyzed to a compound of formula (7) by reaction with a base.
  • a base for example potassium hydroxide.
  • the mixture is maintained at about 60 0 C for about 4-24 hours, for example overnight.
  • the product of formula (7) is isolated and purified by conventional means, for example by acidifying the mixture and collecting the product by filtration.
  • the compounds of formula (6) and (7) can then be used to prepare compounds of Formula L, examples of which are shown in the following reaction schemes.
  • R 3 is oxazole or 1,3-oxazoline
  • the compound of formula (7) is reacted with hydroxyethylamine, and the product cyclized.
  • the compound of formula (7) is reacted with hydroxyethylamine to provide a compound of formula (8).
  • the compound of formula (7) is dissolved in an inert solvent, for example methylene chloride (and N,N-dimethylformamide of necessary to promote solubility), cooled to about 0 0 C, and EDCI (l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) added, followed by HOBT (1-hydroxybenzotriazole hydrate) and a base, for example triethylamine.
  • HOBT 1-hydroxybenzotriazole hydrate
  • a base for example triethylamine
  • the compound of formula (8) is cyclized to provide a compound of Formula I in which R 3 is 1,3-oxazoline.
  • the compound of formula (8) is dissolved in an inert solvent, for example tetrahydrofuran, and Burgess reagent [(methoxycarbonylsulfamoyl)triethylammonium hydroxide] is added. The mixture is maintained at about 70 0 C for about 1-2 hours.
  • the product of Formula I is isolated and purified by conventional means, for example by chromatography.
  • the carboxylic acid of formula (7) can be converted to an acid halide by reaction with oxalyl chloride, for example, which in turn is reacted with a 1- (hydroxyimino)ethylamine derivative.
  • the product (an amino-1-azaprop-l-enyl derivative) is then cyclized conventionally to an oxadiazole derivative of Formula I, as shown in Reaction Scheme VII.
  • the compound of formula (6) is reacted with hydrazine to provide a compound of formula (9).
  • the compound of formula (6) is contacted by hydrazine monohydrate in the absence of a solvent at a temperature about 120 0 C for about 1-6 hours.
  • the product of formula (9) is isolated and purified by conventional means, for example by removal of the solvent under reduced pressure.
  • the compound of formula (9) is suspended in a mixture of a carboxylic acid, for example acetic acid, and a compound of the formula RC(OEt) 3 , and the mixture heated in a microwave at about 120-180 0 C for about 20 minutes.
  • a carboxylic acid for example acetic acid
  • a compound of the formula RC(OEt) 3 is heated in a microwave at about 120-180 0 C for about 20 minutes.
  • the product of Formula I is isolated and purified by conventional means, for example by filtration.
  • the compound of formula (6) is reacted with an amine of formula HNR 5- RI-.6 , in which R 5 and R 6 are as defined above, to provide a compound of Formula I in whichR 3 is an amide.
  • the compound of formula (6) is contacted with an amine of formula HNR 5 R 6 in a protic solvent, for example methanol, at a temperature of about 60 0 C, preferably in a sealed tube, for about 12-24 hours.
  • a protic solvent for example methanol
  • the compound of formula (6) is reacted with an amine of formula FfNR 5 R 6 , in which R 5 and R 6 are as defined above, to provide a compound of Formula I in whichR 3 is an amide.
  • the compound of formula (6) is contacted with an amine of formula HNR 5 R 6 in an inert solvent, for example methylene chloride, in the presence of EDCI (l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride), at room temperature, for about 12-24 hours.
  • EDCI l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • the product of Formula I in which R 3 is an amide of formula -C(O)NR 5 R 6 is isolated and purified by conventional means, for example by removal of the solvent under reduced pressure and chromatography.
  • the compound of formula (7) is reacted with a reagent capable of converting a carboxylic acid to an acid halide, for example thionyl chloride, oxalyl chloride, and the like, to provide a compound of formula (10).
  • a reagent capable of converting a carboxylic acid to an acid halide for example thionyl chloride, oxalyl chloride, and the like
  • the compound of formula (7) is reacted with oxalyl chloride in an inert solvent, for example tetrahydrofuran, initially at a temperature about 0 0 C, then at room temperature for about 12-24 hours.
  • an inert solvent for example tetrahydrofuran
  • N-hydroxy amide oxime of formula (a) is dissolved in an inert solvent, for example tetrahydrofuran, at about 0 0 C, and a hindered amine added, for example N,N- diisopropylethylamine, followed by a compound of formula (10), and the mixture allowed to warm to room temperature, and maintained at that temperature for about 24 hours.
  • an inert solvent for example tetrahydrofuran
  • a hindered amine added for example N,N- diisopropylethylamine
  • the compound of formula (11) is cyclized by heating in an inert solvent, for example toluene, at a temperature of about reflux, for about 24-72 hours.
  • an inert solvent for example toluene
  • the product of formula (11) is isolated and purified by conventional means, for example by preparative thin layer chromatography.
  • the compounds of the invention are A 2A adenosine receptor antagonists, and are effective for treating mammals for various disease states, such as obesity, CNS disorders, including the "movement disorders” (Parkinson's disease, Huntington's Chorea, and catelepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and drag addiction (alcohol, amphetamines, cannabinoids, cocaine, nicotine, and opioids).
  • movement disorders Parkinson's disease, Huntington's Chorea, and catelepsy
  • cerebral ischemia excitotoxicity
  • Utility of the compounds of the invention for the treatment of alcoholism can be tested by determining whether such compounds reduce the incidence of self- administration of ethanol in rats.
  • Utility of the compounds of the invention for the treatment of anxiety can be tested by use of the following published procedures:
  • the elevated plus maze test is a model of anxiety disorder, especially for GAD, panic disorder, agoraphobia and specific phobia Psychopharmacol., 161, 314-323 (2002); Jpn. J. Psychopharmacol., L5, 125-133 (1995), and Pol. J. Pharmacol., 49, 79- 84 (1997);
  • the social interaction test is a model of anxiety disorder, especially for GAD and social phobia, and is described in Physiol. Behav., 71, 551-557 (2000);
  • the vogel conflict test is a model of anxiety disorder, especially for GAD, and is described in Eur. J. Pharmacol, 463, 67-96 (2003);
  • the hole-board test is a model of anxiety disorder, especially for GAD, and is described in Eur. J. Pharmacol, 350, .21-29 (1998), and Pol. J. Pharmacol, 49, 79-84 (1997).
  • the marble burying test is a model of anxiety disorder, especially for OCD, and is described in Jpn. J. Pharmacol 68, 65-70 (1995); and
  • Learned helplessness is a model of anxiety disorder, especially for PTSD, and is described in Green et al., Behavioral models in psychopharmacology: theoretical, industrial, and clinical perspectives, Cambridge University Press, p.21-49 (1991); and Ann. NY Acad. ScL, 821, 332-351, (1997).
  • the compounds of Formula I are usually administered in the form of pharmaceutical compositions.
  • This invention therefore provides pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds of Formula I, or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, solubilizers and adjuvants.
  • the compounds of Formula I may be administered alone or in combination with other therapeutic agents.
  • Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17 th Ed. (1985) and "Modern Pharmaceutics", Marcel Dekker, Inc. 3 rd Ed. (G.S. Banker & CT. Rhodes, Eds.).
  • the compounds of Formula I may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including buccal, intranasal, intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, or as an inhalant.
  • Oral administration is the preferred route for administration of the compounds of Formula 1. Administration may be via capsule or enteric coated tablets, or the like.
  • the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, in can be a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345.
  • Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • Adenosine A 2A receptor antagonists such as the compounds of Formula I are effective over a wide dosage range and is generally administered in a pharmaceutically effective amount.
  • each dosage unit contains from 1 mg to 2 g of an adenosine A 2A receptor antagonist, more commonly from 1 to 700 mg, and for parenteral administration, from 1 to 700 mg of an adenosine A 2A receptor antagonist, more commonly about 2 to 200 mg.
  • the amount of the adenosine A 2A receptor antagonist actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
  • R 3 is Hydrogen
  • R 4 is Hydrogen
  • R 3 is l,3-Oxazorin-2-yl.
  • R 3 is Oxazol-2-yl.
  • R 2 is methyl, and R 3 is acetyl
  • R 2 is methyl, and R 3 is acetyl
  • R 2 is methyl and R 4 is hydrogen
  • Quantity Ingredient (mg/capsule)
  • the above ingredients are mixed and filled into hard gelatin capsules.
  • a tablet formula is prepared using the ingredients below:
  • Quantity Ingredient (mg/tablet)
  • the components are blended and compressed to form tablets.
  • Quantity Ingredient (mg/capsule)
  • the above ingredients are mixed and filled into hard gelatin capsules.
  • a tablet formula is prepared using the ingredients below:
  • Quantity Ingredient (mg/tablet)
  • the components are blended and compressed to form tablets.
  • a dry powder inhaler formulation is prepared containing the following components:
  • the active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.
  • Tablets each containing 30 mg of active ingredient, are prepared as follows:
  • Quantity Ingredient (mg/tablet)
  • the active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly.
  • the solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve.
  • the granules so produced are dried at 50 0 C to 60 0 C and passed through a 16 mesh U.S. sieve.
  • the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
  • Suppositories each containing 25 mg of active ingredient are made as follows: Ingredient Amount
  • the active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.
  • Suspensions each containing 50 mg of active ingredient per 5.0 mL dose are made as follows:
  • a subcutaneous formulation may be prepared as follows:
  • EXAMPLE 28 [0246] An injectable preparation is prepared having the following composition:
  • a topical preparation is prepared having the following composition:
  • the sustained release formulations of this invention are prepared as follows: compound and pH-dependent binder and any optional excipients are intimately mixed(dry-blended). The dry-blended mixture is then granulated in the presence of an aqueous solution of a strong base that is sprayed into the blended powder. The granulate is dried, screened, mixed with optional lubricants (such as talc or magnesium stearate), and compressed into tablets.
  • Preferred aqueous solutions of strong bases are solutions of alkali metal hydroxides, such as sodium or potassium hydroxide, for example sodium hydroxide, in water (optionally containing up to 25% of water-mi scib Ie solvents such as lower alcohols).
  • the resulting tablets may be coated with an optional film-forming agent, for identification, taste-masking purposes and to improve ease of swallowing.
  • the film forming agent will typically be present in an amount ranging from between 2% and 4% of the tablet weight.
  • Suitable film-forming agents are well known to the art and include hydroxypropyl. methylcellulose, cationic methacrylate copolymers (dimethylaminoethyl methacrylate/ methyl-butyl methacrylate copolymers - Eudragit® E - Rohm. Pharma), and the like. These film-forming agents may optionally contain colorants, plasticizers, and other supplemental ingredients.
  • the compressed tablets for example have a hardness sufficient to withstand 8 Kp compression.
  • the tablet size will depend primarily upon the amount of compound in the tablet.
  • the tablets will include from 300 to 1100 mg of compound free base.
  • the tablets will include amounts of compound free base ranging from 400-600 mg, 650-850 mg, and 900-1100 mg.
  • the time during which the compound containing powder is wet mixed is controlled.
  • the total powder mix time i.e. the time during which the powder is exposed to sodium hydroxide solution, will range from 1 to 10 minutes and for example from 2 to 5 minutes.
  • the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60°C.
  • a tritiated adenosine A 2A antagonist 3-(3-hydroxypropyl)-7-methyl-8-(m- methoxystyryl)-l-propargylxanthine, (3H-MSX-2, specific activity: 80 Ci/mmol), was purchased from American Radiolabeled Chemicals, Inc (St. Louis, MO).
  • a tritiated adenosine Aj antagonist, l,3-Dipropyl-8-cyclopentylxanthine ([ 3 H]DPCPX, specific activity: 120 Ci/mmol) was purchased from Perkin Elmer (Boston, MA).
  • a tritiated adenosine A 2a antagonist 4-(2-[7-amino-2-(2-furyl)[l,2,4]triazolo[2,3-a][l,3,5]triazin- 5-ylamino]ethyl)phenol ([ 3 H]ZM241385 specific activity: 27.4 Ci/mmol) was purchased from American Radiolabeled Chemicals, Inc (St. Louis, MO).
  • Adenosine Deaminase (ADA) was purchased from Roche Molecular Biochemicals (Nutley, NJ). GTP was purchased from Sigma.
  • Tris- EDTA buffer 50 mM Tris and 1 mM EDTA, 10 mM MgCl 2 , pH 7.4 for use in experiments.
  • the final content of dimethylsulfoxide in Tris-EDTA buffer during experiments was not more than 1 %.
  • Male Sprague Dawley rats, weighted 250-40Og, 8- 10 weeks old, were purchased from Charles River Labs (Wilmington, MA).
  • HEK293 Human Embryonic Kidney 293 cells stably expressing human A 2A adenosine receptor or human A 2B adenosine receptor were maintained in DMEM supplemented with 10% fetal bovine serum, 2 niM L-glutamine, 100 IU/ml penicillin, 50 ⁇ g/ml streptomycin and 2 ⁇ g/ml puromycin.
  • CHO Choinese Hamster Ovary cells stably expressing human Ai adenosine receptor or human A 3 adenosine receptor were maintained in F12K medium supplemented with 10% fetal bovine serum, 2 mM L- glutamine, 100 IU penicillin, 50 ⁇ g streptomycin and 8 ⁇ g/ml puromycin.
  • PC 12 rat pheochromocytoma cells were cultured in F12K medium supplemented with 10% horse serum and 2.5 % fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 50 ⁇ g/ml streptomycin. All cells were maintained at 37° C in a humidified 5% CO 2 / 95% air incubator and recultivated 2 times per week.
  • the crude membrane was resuspended using buffer HE, and protein concentration was measured by the method of Lowery with BSA as standard. Similar procedures were used for membrane preparation for fresh rat tissues. All experimental procedures were done at 4°C. Membranes were aliquot and kept at -80°C.
  • HEK293 -A 2A cells and PC12 cells were seeded on 150 x 25 mm tissue culture dishes and grown 36 - 72 h to reach ⁇ 80% confluence. Cells were then washed once with PBS and detached with PBS containing 2 niM EDTA. Cells were pelleted at a speed of 1000 rpm and resuspended in Opti-MEM I. ADA (1 U/ml) was added to eliminate adenosine. Cells were loaded into 96-well plates (-6500 cells/well) and incubated with agonist in the absence or presence of antagonists (pretreated for 5 min) for 30 min at 37°C. The cAMP production was measured by using a DiscoveRx kit according to the manufacturer's instructions.
  • This method assesses the ability of an animal to respond to an externally imposed posture after receiving the neuroleptic dopamine D2 antagonist haloperidol.
  • Drugs which are effective in treating Parkinson's disease such as L-DOPA, block haloperidol-induced catalepsy (Mandhane, S. N.; Chopde, C. T.; Ghosh, A. K. (1997).
  • Adenosine A 2A receptors modulate haloperidol-induced catalepsy in rats.
  • the compounds of the invention are prepared in injectable form and diluted to a final concentration using physiological saline. 3,7-Dimethyl-l-propargylxanthine (DMPX) (0, 3 mg/kg) is dissolved in saline. All drugs are administered in a volume of 2 ml/kg. Animals receive three injections: (1) vehicle or compound p.o. 6 hours prior to testing, (2) haloperidol (0.2 mg/kg) i.p. 2.5 hours prior to testing, and (3) vehicle or DMPX (3 mg/kg) 30 minutes prior to testing.
  • DMPX 3,7-Dimethyl-l-propargylxanthine
  • test procedure is as follows:
  • Step I The rat is taken out of the home cage and placed on a table. If the rat failed to move when touched gently on the back or pushed, a score of 0.5 is assigned.
  • Step II The front paws of the rat are placed alternately on a 3 cm high wooden block. If the rat fails to correct this posture within 15 seconds, a score of 0.5 for each paw is added to the score of Step I.
  • Step III The front paws of the rat are placed alternately on a 9 cm high wooden block. If the rat fails to correct the posture within 15 seconds, a score is added to the scores of Step I and II. Thus, for any animal, the highest score obtainable is 3.5 (cut-off score) reflecting total catalepsy.
  • mice receive a unilateral intrastriatal injection of the test compound, vehicle control, and positive control, in a volume of 1.0 .mu.l (15 mice per group). 30 min. after administration of the test compound all mice are systemically administered MPTP (N-methyl-4-phenyl-l,2,5,6-tetrahydropyridine) (25 mg/kg s.c), and this MPTP treatment is repeated 24 hours later. At suitable time points the spontaneous locomotor activity of the animals, as measured in automated activity monitors, is compared with control animals.
  • MPTP N-methyl-4-phenyl-l,2,5,6-tetrahydropyridine
  • test compounds The effects of test compounds on MPTP-induced mesencephalic damage is demonstrated by comparison with dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid levels in caudate tissue taken ipsilateral and contralateral to the test compound injection.
  • the influence of test compounds on MPTP-induced effects on locomotion and catecholamine and metabolite tissue levels is assessed by repeated measures analysis of variance (ANOVA) with appropriate tests.
  • Ethanol dilution (10% v/v) for self- administration is prepared using 95% ethyl alcohol and tap water.
  • Sucrose solution (10 % w/v) is prepared using tap water.
  • the test compound is dissolved in warm saline, and administered in a 1 ml/kg volume.
  • Ethanol operant self-administration is carried out in standard operant chambers (Med Associates, Georgia, VT) housed in sound-attenuated cubicles.
  • Each chamber contains two retractable levers against the right wall, 7 cm from the floor and 1 cm from the right or left edge of the right wall, respectively.
  • One recessed dish positioned at 2.5 cm above floor level and 6 cm from the levers towards the center of the chamber is the reinforcer receptacle.
  • Fluid (0.1 ml) is delivered from 10 syringe pumps upon activation of 1 of the 2 retractable response levers.
  • a 3 second tone is activated upon lever pressing. Pressing the inactive lever resulted in no visual/auditory cue or reinforcement delivery, except during sucrose overnight sessions.
  • the beginning of a training session is signaled by the onset of the house light located in the center of the wall facing the levers, at 27.2 cm above the floor.
  • rats begin the operant self-administration training. Animals are kept on water restriction for the next 4-5 days, during which they receive one 45 minute session per day on an FRl schedule with 10% ethanol solution as a reinforcer and one active lever. They are then given free water in their home cages for the remainder of the experiment and are trained for 2-3 more of the above described sessions. The next day, sessions are shortened to 30 minutes and the ratio of responding was increased to an FR3 schedule. Ethanol is added to the sweet solution (10% sucrose/10% ethanol), and rats receive 3-4 sessions of this solution, followed by at least 20 sessions with 10% ethanol only. A minimum average of 0.3 g/kg ethanol consumption in 8 sessions prior to the beginning of any drug treatment is required.
  • the Wistar-derived rats receive several doses of the test compound (0.00, 7.5, 10, and 15 mg/kg) administered intraperitonealy (i.p.), and a positive control compound, mecamylamine (1.5 mg/kg, subcutaneously (s.c).
  • the compounds are administered 30 minutes prior to SA sessions.
  • the test compound is administered at 2 ml/kg for the 7.5 mg/kg (3.75 mg/ml) and 10 mg/kg (5 mg/ml), doses, and at 3 ml/kg for the 15 mg/kg dose (5 mg/ml).
  • the compound is dissolved in corn oil (VEH), and sonicated for at least 30-minutes, up to 2 hours prior to administration.
  • Mecamylamine is dissolved in 0.09% isotonic saline and administered at a volume of 1 ml/kg.
  • Apparatus Food training and nicotine self-administration take place in 8 standard Coulbourn operant chambers. Each chamber is housed in a sound-attenuated box. Operant chambers are equipped with two levers, mounted 2 cm above the floor, and a cue light mounted 2 cm above the right lever on the back wall of the chamber. For food training, a food hopper is located 2-cm to the left/right of either lever, in the middle of the back wall. Intravenous infusions are delivered in a volume of 0.1 ml over a 1 second interval via an infusion pump (Razel, CT) housed outside of the sound attenuated chamber.
  • Razel, CT infusion pump
  • Rats are anesthetized with a ketamine/xylazine mixture and chronic silastic jugular catheters are inserted into the external jugular vein and passed subcutaneously to a polyethylene assembly mounted on the animal's back.
  • the catheter assembly consists of a 13-cm length of silasitic tubing (inside diameter 0.31 mm; outside diameter 0.64 mm), attached to a guide cannula that is bent at a right angle.
  • the cannula is embedded into a dental cement base and anchored with a 2 x 2 cm square of durable mesh.
  • the catheter is passed subcutaneously from the rats back to the jugular vein where it is inserted and secured with a non-absorbable silk suture.
  • rats Upon successful completion of surgery, rats are given 3-5 days to recover before self- administration sessions starts. During the recovery period, rats remain ad libitum food access, and have catheter lines flushed daily with 30 units/ml of heparinized saline containing 66 mg/ml of Timentin to prevent blood coagulation and infection in the catheters.
  • Nicotine Self-Administration Following successful recovery from catheter implant surgery, rats are again food deprived to 85% of their free-feeding body weight. Once self-administration sessions begin, subjects are trained to IV self-administer nicotine in 1-hour baseline sessions, 5 days per week, under a FR1-TO-20 schedule of reinforcement until stable responding is achieved. Stable responding is defined as less than 20% variability across 3 consecutive sessions. After acquisition of stable responding for nicotine, various doses of the test compound is tested using a within- subjects Latin square design. Rats are allowed to self-administer nicotine after treatment with each dose of test compound for 1 test session, and subsequently "rebaselined" for 1-3 days before the next dose probe during one test self- administrations sessions. Following the testing of the first compound, rats receive the positive control compound, mecamylamine (1.5 rng/kg), administered according to a crossover design.
  • mecamylamine 1.5 rng/kg

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouveaux composés qui sont des antagonistes du récepteur A2A de l'adénosine, et leur utilisation dans le cadre du traitement de divers états pathologiques chez les mammifères, tels que l'obésité, les troubles du SNC, y compris les 'troubles du mouvement' (la maladie de Parkinson, la chorée d'Huntington, et la catalepsie), et l'ischémie cérébrale, l'excitotoxicité, les troubles cognitifs et physiologiques, la dépression, le TDAH et la toxicomanie (alcool, amphétamine, cannabinoïdes, cocaïne, nicotine et opioïdes), et leur utilisation pour l'amplification de la réponse immunitaire. L'invention concerne également des procédés de préparation de tels composés et des compositions pharmaceutiques les contenant.
EP07757782A 2006-03-02 2007-03-02 Antagonistes du recepteur a2a de l'adenosine Ceased EP1989210A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77882106P 2006-03-02 2006-03-02
US81574506P 2006-06-21 2006-06-21
PCT/US2007/063143 WO2007103776A2 (fr) 2006-03-02 2007-03-02 Antagonistes du recepteur a2a de l'adenosine

Publications (1)

Publication Number Publication Date
EP1989210A2 true EP1989210A2 (fr) 2008-11-12

Family

ID=38475714

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07757782A Ceased EP1989210A2 (fr) 2006-03-02 2007-03-02 Antagonistes du recepteur a2a de l'adenosine

Country Status (5)

Country Link
US (1) US20070208040A1 (fr)
EP (1) EP1989210A2 (fr)
JP (1) JP2009528389A (fr)
CA (1) CA2644996A1 (fr)
WO (1) WO2007103776A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
EP2121705A2 (fr) 2006-12-01 2009-11-25 Cv Therapeutics, Inc. Antagonistes du récepteur d'adénosine a2a
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
GB0718434D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
US20100093723A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093722A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US8835442B2 (en) 2009-11-18 2014-09-16 Council Of Scientific & Industrial Research 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2H-thiazolo [4,5-di pyrimidin-6-yl—and process for preparation thereof
KR102033806B1 (ko) * 2011-11-11 2019-10-17 길리어드 아폴로, 엘엘씨 Ａｃｃ 억제제 및 이의 용도
WO2014182950A1 (fr) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Inhibiteurs de l'acc et utilisations associées
HK1221411A1 (zh) 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc抑制剂和其用途
KR20160005365A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
EA201591959A1 (ru) * 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение
JP2016532721A (ja) * 2013-10-07 2016-10-20 バイエル ファーマ アクチエンゲゼルシャフト 環状チエノウラシルカルボキサミドおよびその使用
WO2015164383A1 (fr) 2014-04-22 2015-10-29 Q-State Biosciences, Inc. Modèles pour des études concernant la maladie de parkinson
EP3180345B1 (fr) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Dérivés thieno- et furo[2,3-d]pyrimidine-2,4[1h,3h]-dione en tant que modulateurs trpc5 pour le traitement de maladies neuropsychiatriques
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EP3380478B1 (fr) 2015-11-25 2020-12-23 Gilead Apollo, LLC Inhibiteurs de l'acc à base d'esters et utilisations associées
BR112018010453B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Compostos triazólicos inibindores de acetil coa carboxilase (acc)
KR20180086191A (ko) 2015-11-25 2018-07-30 길리어드 아폴로, 엘엘씨 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물
EA201890913A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс Пиразоловые соединения в качестве ингибиторов акк и их применение
AU2017226267B2 (en) 2016-03-02 2021-06-24 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof
WO2018041771A1 (fr) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft Thiéno-uraciles substitués par un groupe (1-méthylcyclopropyl)méthyle et leur utilisation
MX2019003351A (es) 2016-09-23 2019-08-05 Bayer Ag Tienouracilos n3-ciclicamente sustituidos y uso de los mismos.
CN108341830B (zh) 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
EP4122464B1 (fr) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Combinaisons thérapeutiques pour le traitement des maladies du foie
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
EP3660023B1 (fr) * 2017-07-26 2023-03-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Composés de thiénopyrimidinedione utilisés en tant qu'inhibiteurs d'acc et leur utilisation
WO2020139803A1 (fr) * 2018-12-24 2020-07-02 Dcb-Usa Llc Dérivés de benzothiadiazine et compositions les comprenant pour traiter des troubles médiés par l'adénosine
CN113924303B (zh) 2019-07-02 2023-10-20 广东东阳光药业股份有限公司 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
KR910005856B1 (ko) * 1987-09-16 1991-08-05 다이호야꾸힝고오교가부시끼가이샤 티에노피리미딘 유도체
DK522187D0 (da) * 1987-10-06 1987-10-06 Ferrosan As Imidozothienopyrimidiner, deres fremstilling og anvendelse
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
CA2339664A1 (fr) * 1998-08-28 2000-03-09 Astrazeneca Ab Nouveaux composes
CN1187354C (zh) * 1999-11-12 2005-02-02 拜奥根有限公司 腺苷受体拮抗剂以及制造和使用它们的方法
EP1261327B1 (fr) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Modulateurs de recepteurs de l'adenosine
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
WO2002064598A1 (fr) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles
WO2003050241A2 (fr) * 2001-12-12 2003-06-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Procedes d'utilisation d'inhibiteurs de l'adenosine extracellulaire et d'inhibiteurs de recepteur de l'adenosine aux fins d'amelioration de reponse immune et d'inflammation
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
BR0312943A (pt) * 2002-07-17 2005-07-12 Warner Lambert Co Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
JP2006502992A (ja) * 2002-07-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ−１３のアロステリック阻害剤とセレコキシブ又はバルデコキシブとの組合せ
PT1622908E (pt) * 2003-05-06 2008-11-14 Cv Therapeutics Inc Derivados de xantina como antagonistas do receptor a2b de adenosina
KR100765565B1 (ko) * 2003-05-21 2007-10-09 에프. 호프만-라 로슈 아게 벤조티아졸 유도체 및 그의 아데노신 에이2에이 수용체에관련된 질병의 치료에서의 용도
EP1678181B1 (fr) * 2003-10-31 2008-12-31 Cv Therapeutics, Inc. Antagonistes du recepteur de l'adenosine a2b
US7523193B2 (en) * 2004-05-18 2009-04-21 International Business Machines Corporation Method and apparatus for DNS pre-fetching for multiple clients
EP2121705A2 (fr) * 2006-12-01 2009-11-25 Cv Therapeutics, Inc. Antagonistes du récepteur d'adénosine a2a

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007103776A2 *

Also Published As

Publication number Publication date
JP2009528389A (ja) 2009-08-06
US20070208040A1 (en) 2007-09-06
WO2007103776A3 (fr) 2007-12-13
CA2644996A1 (fr) 2007-09-13
WO2007103776A2 (fr) 2007-09-13

Similar Documents

Publication Publication Date Title
US20070208040A1 (en) A2a adenosine receptor antagonists
US6825349B2 (en) A2B adenosine receptor antagonists
US7125993B2 (en) A2B adenosine receptor antagonists
AU2007227021B2 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
US7449473B2 (en) Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
US20030229106A1 (en) A2B adenosine receptor antagonists
US20130123280A1 (en) A2b adenosine receptor antagonists
US7776868B2 (en) Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
JP2006502984A (ja) ヘテロ環により置換されているイミダゾトリアジン類
US7951813B2 (en) Quinazolinone derivatives as ALDH-2 inhibitors
ES2363672T3 (es) TRIAZOLO[1,5-a]QUINOLINAS COMO LIGANDOS DEL RECEPTOR A3 DE ADENOSINA.
WO2012119979A1 (fr) Dérivés de 1h-pyrrolo[3,2-d]pyrimidinedione
AU2011202523B2 (en) A2B adenosine receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080901

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20081204

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PARKHILL, ERIC

Inventor name: KOBAYASHI, TETSUYA

Inventor name: PERRY, THAO

Inventor name: LI, XIAOFEN

Inventor name: ZABLOCKI, JEFF

Inventor name: KALLA, RAO

Inventor name: ELZEIN, ELFATIH

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126187

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PARKHILL, ERIC

Inventor name: KOBAYASHI, TETSUYA

Inventor name: PERRY, THAO

Inventor name: LI, XIAOFEN

Inventor name: ZABLOCKI, JEFF

Inventor name: KALLA, RAO

Inventor name: ELZEIN, ELFATIH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20111119

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1126187

Country of ref document: HK